Literature DB >> 17851858

Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.

David Loven1, Einat Be'ery, Rinat Yerushalmi, Claude Koren, Aaron Sulkes, Idit Lavi, Yuval Shaked, Eyal Fenig.   

Abstract

UNLABELLED: Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored.
MATERIALS AND METHODS: The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation.
RESULTS: We found a significant decrease in VEGF and PDGF-BB serum levels during the combination treatment (p < 0.0001), followed by an increase in the successive rest-period (p < 0.0001). In addition, substantial changes in platelets counts were observed during treatment in correlation with the changes of VEGF and PDGF-BB serum levels. DISCUSSION: These results suggest that combined chemo-irradiation affect levels of pro-angiogenic factors during treatment, and may reflect an anti-angiogenic window induced during this treatment. The potential implications of this inducible phenomenon, including a possible clinical benefit from the administration of long lasting metronomic chemotherapy immediately following combined chemo-irradiation, would warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17851858     DOI: 10.1080/02841860701472470

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

Review 1.  Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Cancer Res       Date:  2019-08-20       Impact factor: 12.701

2.  Aptamer-nanoparticle assembly for logic-based detection.

Authors:  Mohammed I Shukoor; Meghan O Altman; Da Han; Abdullah Tahir Bayrac; Ismail Ocsoy; Zhi Zhu; Weihong Tan
Journal:  ACS Appl Mater Interfaces       Date:  2012-06-18       Impact factor: 9.229

3.  Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial.

Authors:  M Verstraete; A Debucquoy; J Dekervel; J van Pelt; C Verslype; E Devos; G Chiritescu; K Dumon; A D'Hoore; O Gevaert; X Sagaert; E Van Cutsem; K Haustermans
Journal:  Br J Cancer       Date:  2015-03-17       Impact factor: 7.640

4.  Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy.

Authors:  Roberto J Arai; Vanessa Petry; Paulo M Hoff; Max S Mano
Journal:  Biomark Res       Date:  2018-06-14

5.  Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab.

Authors:  Christine Vestergaard Madsen; Karina Dahl Steffensen; Dorte Aalund Olsen; Marianne Waldstrøm; Maja Smerdel; Parvin Adimi; Ivan Brandslund; Anders Jakobsen
Journal:  J Ovarian Res       Date:  2012-09-19       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.